Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Galapagos ( (GLPG) ) is now available.
Galapagos reported its full-year 2025 results on February 23, 2026, highlighting a strategic reset centered on winding down its cell therapy business and pivoting to business development-led growth. The company closed 2025 with about €3.0 billion in cash and financial investments, expects 2026 year-end cash of €2.775–€2.85 billion, and aims to be cash flow neutral to positive by late 2026 after restructuring costs.
Management detailed that the wind-down of its cell therapy activities, formally initiated after works council consultations concluded on January 5, 2026, is on schedule and should be substantially completed by the end of the third quarter of 2026. The remaining organization is expected to be a lean team of 35–40 employees by end-2026, with Galapagos repositioned to pursue transformational deals in areas of high unmet medical need.
Governance changes in late 2025 included new executive and board appointments, such as a new General Counsel and several new non-executive directors, alongside the departure of multiple board members. These moves, together with the appointment of CEO Henry Gosebruch in May 2025 and further board refreshment in early 2026, underscore a broader governance overhaul intended to support the new strategic direction.
In its immunology portfolio, Galapagos reported that December 2025 topline Phase 2 data for TYK2 inhibitor GLPG3667 in dermatomyositis met its primary endpoint and showed meaningful improvements on multiple secondary measures with a favorable safety profile. In systemic lupus erythematosus, GLPG3667 did not achieve a statistically significant dose-response on the primary SRI-4 endpoint but delivered numerical benefits on several secondary, particularly skin-related, outcomes, with final 48-week data pending in the second quarter of 2026.
As part of the strategy to maximize value from its TYK2 program, the company is actively evaluating partnership and business development options to advance GLPG3667 in dermatomyositis and exploring expansion into additional severe autoimmune indications. In oncology, Galapagos has terminated its Phase 1/2 CAR-T trials ATALANTA-1 and PAPILIO-1 in connection with the cell therapy exit, with patients transitioning into the HESPERIA long-term follow-up study and only minimal residual spending anticipated.
Financially, Galapagos swung from an operating loss of €188.3 million in 2024 to an operating profit of €295.1 million in 2025, mainly driven by the release of €1.069 billion in deferred income from its drug discovery platform collaboration. Total net revenues surged 304% year-on-year to €1.112 billion, collaboration revenues climbed sharply, and the company reported net profit of €320.9 million versus €74.1 million in 2024, despite higher R&D and an impairment charge for the cell therapy activities.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos’ overall stock score reflects a challenging financial and operational landscape. The company’s strong cash position and strategic partnerships are positive, but are overshadowed by significant operating losses, poor valuation metrics, and technical indicators suggesting potential downward pressure. Investors should be cautious and monitor the company’s ability to execute its strategic transformation and improve financial performance.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a Belgium-based biopharmaceutical company listed on Euronext and Nasdaq that focuses on discovering and developing novel therapeutic medicines, with a particular emphasis on immunology and severe autoimmune diseases. The company has historically invested in cell therapy and small molecule pipelines and maintains a strategic collaboration with U.S. biotech group Gilead, while operating from its headquarters in Mechelen and hubs in Chicago and San Francisco.
Average Trading Volume: 98,759
Technical Sentiment Signal: Buy
Current Market Cap: $2.25B
For an in-depth examination of GLPG stock, go to TipRanks’ Overview page.